Small-Molecule PanK Modulators for Tunable CoA Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective modulators of pantothenate kinase (PanK) to investigate the role of CoA levels in diseases such as PanK-associated neurodegeneration (PKAN) and diabetes, as current tools are insufficient for modulating CoA levels to address these conditions.
Innovation Solution
Development of small molecule modulators of PanK, including specific compounds represented by various structural formulas, to modulate PanK activity and CoA levels, which can be used in pharmaceutical compositions for treating disorders associated with PanK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If genetic deletion of Pank1 is used to reduce hepatic CoA levels, then CoA supply is limited and fatty acid oxidation decreases, but this results in fasting hypoglycemia and early death
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate PanK activity instead of complete genetic deletion. These compounds provide graded inhibition that can be tuned to achieve therapeutic CoA reduction without completely eliminating PanK function, thereby avoiding the lethal effects of total deletion while still achieving the desired metabolic modulation.
Solution Approach 2:
The patent changes the parameter of PanK activity from complete absence (genetic deletion) to partial modulation (pharmacological inhibition). By using small molecule inhibitors that can be administered at varying doses, the patent achieves continuous adjustment of CoA levels, allowing optimization between therapeutic efficacy and safety margins.
2Reliability
If PanK activity is completely inhibited to reduce CoA levels for treating PKAN, then neuronal metabolism improves, but this may cause harmful effects on other tissues expressing PanK isoforms
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target PanK2 in neuronal tissues while sparing other PanK isoforms in non-neuronal tissues. This is achieved through exploiting the unique structural features of PanK2 that are critical for its function in neuronal CoA synthesis but less critical in other tissues, allowing selective modulation without systemic harm.
Solution Approach 2:
The patent employs partial action by using sub-maximal inhibition of PanK activity. Instead of completely blocking PanK function, the compounds achieve partial inhibition sufficient to raise CoA levels in PKAN patients while leaving enough residual activity to maintain essential functions in other tissues, thereby avoiding excessive action and its harmful consequences.
3Quantity of substance
If small molecule modulators are developed to selectively target PanK2, then neuronal CoA levels can be increased, but this requires high structural specificity to avoid affecting other PanK isoforms
Solution Approach 1:
The patent uses structure-activity relationship (SAR) studies to create simplified copies or analogs of natural PanK substrates and inhibitors. By copying key structural features that confer selectivity for PanK2 and systematically modifying them, the patent achieves high structural specificity without requiring overly complex molecular structures, thereby balancing manufacturability with selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed compounds effectively modulate PanK activity, providing therapeutic potential for disorders like PKAN and diabetes by regulating CoA levels, thereby addressing the underlying metabolic imbalances.
Implementation Method 1
Pantothenate Kinase (PanK, EC 2.7.1.33) catalyzes the biochemical conversion of pantothenate (vitamin B5) to phosphopantothenate and thereby initiates the biosynthesis of coenzyme A (CoA)
Data Source
AI summary
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment.